Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTONATE: Intensified protocol for lupus nephritis with rituximab and no maintenance therapy
2021-006544-26Phase 3Terminated
- Sponsor
- ASL Città di Torino
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, mycophenolate mofetil and cyclophosphamide in lupus nephritis (LN) (2 arms), sponsored by ASL Città di Torino. Primary endpoint: Renal response / efficacy comparison between IBCDT vs standard regimen. Started May 2022; status: terminated.
02
Drugs
rituximabmycophenolate mofetilcyclophosphamide
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2021-006544-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006544-26.